Locate Bio obtains multiple late stage orthobiologics assets from RCSI

By Nikita Chaurasia  | Date: 2020-09-23

Locate Bio obtains multiple late stage orthobiologics assets from RCSI

Regenerative medicine major, Locate Bio, has reportedly announced its in-licensing of several late stage orthobiologics assets from the RCSI University of Medicine and Health Sciences.

Sources state that the technologies created by the RCSI Tissue Engineering Research Group have wide human and pre-clinical data which efficaciously demonstrates their effectiveness in the treatment of both, soft and hard, tissues. The RCSI licensing transaction comprises natural collagen-based, best in class, and proprietary delivery technologies, that have been developed into numerous products for the regeneration of cartilage tissues, regeneration of bone, and the treatment of infections.

According to John von Benecke, the CEO of Locate Bio, the company is thrilled by the addition of these late stage, high-quality, and complementary products to its portfolio. He has further stated that this is a significant step in the company’s drive towards the development of a world leading orthobiologics enterprise, with its key platforms now covering numerous key areas across the clinical use waterfront.

Locate Bio continues to make excellent advancement toward spinal fusion with its lead product and eagerly looks ahead towards bringing these new assets via the process of regulatory approval in the forthcoming years, added Benecke.

Reliable sources state that Locate’s in-licencing of the assets from RCSI delivers additional breadth and depth to its existing orthobiologics portfolio, further accelerating its route to market. The company is reportedly in search of additional in-licencing or complementary acquisition opportunities that would widen its portfolio of giving surgeons the choice of best-in-class products and technologies that address the existing challenges of present products, also meeting the specific patient clinical requirement.

Ian Wilding, the Chairman at Locate Bio, has stated that the acquisition of these late stage orthobiologics assets progresses Locate’s aspirations and is another significant step in the company’s strategy towards the development of a complementary and differentiated portfolio of innovative products, with high value, strong IP, and a well-state path to market.

 

Source Credits:

https://www.locatebio.com/locate-bio-acquires-complementary-late-stage-orthobiologics-assets/

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More >>

More News By Nikita Chaurasia

Swiftly achieves Unicorn status with $100M Series C led by BRV Capital

Swiftly achieves Unicorn status with $100M Series C led by BRV Capital

By Nikita Chaurasia

Swiftly Systems has reportedly achieved unicorn status, securing in funding through a Series C round. The prominent BRV Capital Management led this funding initiative. According to the earlier reports, Swiftly was adopted by hundreds of consumer b...

Rainforest nations unify to demand cash for climate & biodiversity preservation

Rainforest nations unify to demand cash for climate & biodiversity preservation

By Nikita Chaurasia

As per the reports, twelve nations with rainforests united to establish a collective initiative aiming to address climate change and safeguard biodiversity at summit held in Brazil. The declaration, titled "United for Our Forests," emerged ...

AI Chatbot, Llama 2, unveiled by Meta for commercial use via Microsoft

AI Chatbot, Llama 2, unveiled by Meta for commercial use via Microsoft

By Nikita Chaurasia

Meta Platforms has recently introduced Llama 2, an artificial intelligence large language model, for commercial use in collaboration with major cloud providers like Microsoft. Instead of charging for access or usage, Meta aims to share the model with...

Moderna signs agreement to explore mRNA medicines in China

Moderna signs agreement to explore mRNA medicines in China

By Nikita Chaurasia

Moderna Inc, a leading vaccine manufacturer, reportedly announced on Wednesday that it has entered into a memorandum of understanding (MoU) and a land collaboration agreement aimed at exploring opportunities for researching, developing, and producing...

Nike and Epic Games collaborate to launch Airphoria NFT in Fortnite

Nike and Epic Games collaborate to launch Airphoria NFT in Fortnite

By Nikita Chaurasia

The American footwear design & manufacturing company, Nike and Epic Games, the creators of the popular online game Fortnite, have joined forces in an exciting new collaboration. The partnership aims to bring about a groundbreaking change in the d...